XRD-0394
/ XRad Therap
- LARVOL DELTA
Home
Next
Prev
1 to 11
Of
11
Go to page
1
December 02, 2025
ATM/DNA-PK Inhibitor XRD-0394 Enhances Radiation-Induced Pro-Inflammatory Responses in Glioma Models
(SNO 2025)
- "We previously evaluated the radiosensitizing effect of the ATM inhibitor AZD1390 in both p53-mutant and wild-type DMGs and observed enhanced sensitivity in p53-mutant models (Mangoli et al., in press). In conclusion, a dual inhibitor of ATM and DNA-PK enhances radiation-induced cytotoxicity and pro-inflammatory signaling in GBM and DMG models. Ongoing studies will further define the therapeutic potential of this combination strategy."
IO biomarker • Ataxia • Brain Cancer • Diffuse Midline Glioma • Glioblastoma • Glioma • High Grade Glioma • Immunology • Inflammation • Movement Disorders • Primary Immunodeficiency • Solid Tumor • CCR4 • STING
November 06, 2025
ATM/DNA-PK Inhibitor XRD-0394 Enhances Radiation-Induced Pro-Inflammatory Responses in Glioma Models
(WFNOS 2025)
- "We previously evaluated the radiosensitizing effect of the ATM inhibitor AZD1390 in both p53-mutant and wild-type DMGs and observed enhanced sensitivity in p53-mutant models (Mangoli et al., in press). In conclusion, a dual inhibitor of ATM and DNA-PK enhances radiation-induced cytotoxicity and pro-inflammatory signaling in GBM and DMG models. Ongoing studies will further define the therapeutic potential of this combination strategy."
IO biomarker • Ataxia • Brain Cancer • Diffuse Midline Glioma • Glioblastoma • Glioma • Immunology • Inflammation • Movement Disorders • Oncology • Primary Immunodeficiency • Solid Tumor • CCR4 • STING
November 06, 2025
ATM/DNA-PK Inhibitor XRD-0394 Enhances Radiation-Induced Pro-Inflammatory Responses in Glioma Models
(WFNOS 2025)
- "We previously evaluated the radiosensitizing effect of the ATM inhibitor AZD1390 in both p53-mutant and wild-type DMGs and observed enhanced sensitivity in p53-mutant models (Mangoli et al., in press). In conclusion, a dual inhibitor of ATM and DNA-PK enhances radiation-induced cytotoxicity and pro-inflammatory signaling in GBM and DMG models. Ongoing studies will further define the therapeutic potential of this combination strategy."
IO biomarker • Ataxia • Brain Cancer • Diffuse Midline Glioma • Glioblastoma • Glioma • High Grade Glioma • Immunology • Inflammation • Movement Disorders • Primary Immunodeficiency • Solid Tumor • CCR4 • STING
February 18, 2025
Concurrent XRD-0394 With Radiation Therapy for High Grade Gliomas
(clinicaltrials.gov)
- P1 | N=39 | Not yet recruiting | Sponsor: NYU Langone Health
New P1 trial • Brain Cancer • CNS Tumor • Glioma • Malignant Glioma • Oncology • Solid Tumor
March 06, 2024
First disclosure of XRD-0394, a novel dual ATM/DNA-PK inhibitor, that potently radiosensitizes and potentiates PARP and topoisomerase inhibitors
(AACR 2024)
- P1 | "The median tmax (2.3 h) and mean terminal t½ (11.1 h) at the 160 mg dose in subjects support coadministration of XRD-0394 and RT within a clinically feasible time frame. These results provide a rationale for future clinical trials with XRD-0394 in combination with RT, RT and immunotherapy, PARP inhibitors and targeted delivery of topoisomerase inhibitors."
IO biomarker • Late-breaking abstract • Oncology • BRCA
April 09, 2024
A novel dual ATM/DNA-PK inhibitor, XRD-0394, potently radiosensitizes and potentiates PARP and topoisomerase I inhibitors.
(PubMed, Mol Cancer Ther)
- P1 | "A Phase Ia clinical trial (NCT05002140) with XRD-0394 in combination with RT has completed. These results provide a rationale for future clinical trials with XRD-0394 in combination with RT, PARP inhibitors and targeted delivery of topoisomerase I inhibitors."
Journal • Oncology • BRCA1 • BRCA2
January 11, 2024
Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients
(clinicaltrials.gov)
- P1 | N=12 | Completed | Sponsor: XRad Therapeutics Inc | Active, not recruiting ➔ Completed | Trial completion date: Dec 2023 ➔ Jul 2023 | Trial primary completion date: Dec 2023 ➔ Jul 2023
Combination therapy • Metastases • Trial completion • Trial completion date • Trial primary completion date • Oncology • Solid Tumor
July 17, 2023
Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients
(clinicaltrials.gov)
- P1 | N=11 | Active, not recruiting | Sponsor: XRad Therapeutics Inc | Recruiting ➔ Active, not recruiting | N=38 ➔ 11
Enrollment change • Enrollment closed • Oncology • Solid Tumor
February 08, 2023
Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients
(clinicaltrials.gov)
- P1 | N=38 | Recruiting | Sponsor: XRad Therapeutics Inc | Trial completion date: Dec 2022 ➔ Dec 2023 | Trial primary completion date: Dec 2022 ➔ Dec 2023
Combination therapy • Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor
August 25, 2021
XRad Therapeutics Announces First Patient Dosed in Phase 1a Clinical Trial of XRD-0394 for Metastatic, Locally-Advanced or Recurrent Solid Tumors
(GlobeNewswire)
- “XRad Therapeutics…announced that the first patient has been dosed in the company’s Phase 1a trial evaluating XRD-0394 in combination with radiation therapy (RT) for the treatment of metastatic, locally-advanced or recurrent solid tumors. XRD-0394 is a first-in-class, oral, dual kinase inhibitor of both ataxia-telangiectasia mutated (ATM) and DNA-dependent protein kinase (DNA-PK) and based on preclinical studies is designed to enhance the effectiveness of radiation therapies…The Phase 1a trial is an open-label, multicenter study designed to evaluate the safety and tolerability of single ascending doses of XRD-0394 administered with palliative RT in patients with metastatic, locally advanced or recurrent cancer.”
Trial status • Oncology • Solid Tumor
August 12, 2021
Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients
(clinicaltrials.gov)
- P1; N=38; Recruiting; Sponsor: XRad Therapeutics Inc
New P1 trial • Oncology • Solid Tumor
1 to 11
Of
11
Go to page
1